CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar Long-term effects of intensive glucose lowering on cardiovascular outcomes Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Simple Electrocardiographic Measures Improve Sudden Arrhythmic Death Prediction in Coronary Disease Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop

Consensusolume 41, Issue 24, 21 June 2020, Pages 2313–2330

JOURNAL:Eur Heart J. Article Link

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

J Borén, MJ Chapman, RM Krauss et al. Keywords: low-density lipoprotein; ASCVD; statin; mechanisms

Full Text PDF